Insights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs

被引:0
|
作者
Liang, Shuang [1 ]
Wang, Xianying [1 ]
Zhu, Xiuqing [2 ,3 ]
机构
[1] Hebei Med Univ, Hosp 3, Dept Pharm, Shijiazhuang, Peoples R China
[2] Guangzhou Med Univ, Key Lab Neurogenet & Channelopathies, Guangdong Prov & Minist Educ China, Guangzhou, Peoples R China
[3] Guangzhou Med Univ, Affiliated Brain Hosp, Dept Pharm, Guangzhou, Peoples R China
关键词
NSAIDs; cardiovascular safety signals; FAERS; OpenVigil; 2.1; pharmacovigilance; pharmacodynamics; cyclooxygenase-1; cyclooxygenase-2; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COX-2; INHIBITORS; DISEASE; RISK;
D O I
10.3389/fphar.2024.1455212
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Aim Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat fever, pain, and inflammation. Concerns regarding their cardiovascular safety have been raised. However, the underlying mechanism behind these events remains unknown. We aim to investigate the cardiovascular safety signals and receptor mechanisms of NSAIDs, employing a comprehensive approach that integrates pharmacovigilance and pharmacodynamics.Methods This study utilized a pharmacovigilance-pharmacodynamic approach to evaluate the cardiovascular safety of NSAIDs and explore potential receptor mechanisms involved. Data were analyzed using the OpenVigil 2.1 web application, which grants access to the FDA Adverse Event Reporting System (FAERS) database, in conjunction with the BindingDB database, which provides target information on the pharmacodynamic properties of NSAIDs. Disproportionality analysis employing the Empirical Bayes Geometric Mean (EBGM) and Reporting Odds Ratio (ROR) methods was conducted to identify signals for reporting cardiovascular-related adverse drug events (ADEs) associated with 13 NSAIDs. This analysis encompassed three System Organ Classes (SOCs) associated with the cardiovascular system: blood and lymphatic system disorders, cardiac disorders, and vascular disorders. The primary targets were identified through the receptor-NSAID interaction network. Ordinary least squares (OLS) regression models explored the relationship between pharmacovigilance signals and receptor occupancy rate.Results A total of 201,231 reports of cardiovascular-related ADEs were identified among the 13 NSAIDs. Dizziness, anemia, and hypertension were the most frequently reported Preferred Terms (PTs). Overall, nimesulide and parecoxib exhibited the strongest signal strengths of ADEs at SOC levels related to the cardiovascular system. On the other hand, our data presented naproxen and diclofenac as drugs of comparatively low signal strength. Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) were identified as central targets. OLS regression analysis revealed that the normalized occupancy rate for either COX-1 or COX-2 was significantly inversely correlated with the log-transformed signal measures for blood and lymphatic system disorders and vascular disorders, and positively correlated with cardiac disorders and vascular disorders, respectively. This suggests that higher COX-2 receptor occupancy is associated with an increased cardiovascular risk from NSAIDs.Conclusion Cardiovascular safety of NSAIDs may depend on pharmacodynamic properties, specifically, the percentage of the occupied cyclooxygenase isoenzymes. More studies are needed to explore these relations and improve the prescription process.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Cardiovascular effects and safety of (non-aspirin) NSAIDs
    Schjerning, Anne-Marie
    McGettigan, Patricia
    Gislason, Gunnar
    NATURE REVIEWS CARDIOLOGY, 2020, 17 (09) : 574 - 584
  • [2] Cardiovascular safety of NSAIDs
    Ray, Wayne A.
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 342
  • [3] Cardiovascular safety of NSAIDs
    Harbin, Megan
    Turgeon, Ricky D.
    Kolber, Michael R.
    CANADIAN FAMILY PHYSICIAN, 2014, 60 (03) : E166 - E166
  • [4] Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view
    Pepine, Carl J.
    Gurbel, Paul A.
    CLINICAL CARDIOLOGY, 2017, 40 (12) : 1352 - 1356
  • [5] Comparison of two drug safety signals in a pharmacovigilance data mining framework
    Tubert-Bitter, Pascale
    Begaud, Bernard
    Ahmed, Ismail
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2016, 25 (02) : 615 - 629
  • [6] NSAIDs Prescription Prevalence after a Cardiovascular Event Related Hospitalization in Medicaid Beneficiaries from Puerto Rico
    Velez, Suzette M.
    Hernandez-Munoz, Jose J.
    Davis, Sasha M.
    Almodovar, Maria G.
    Mercado, Jose R.
    PUERTO RICO HEALTH SCIENCES JOURNAL, 2016, 35 (04) : 209 - 214
  • [7] Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006
    Lapeyre-Mestre, Maryse
    Grolleau, Sabrina
    Montastruc, Jean-Louis
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 (02) : 223 - 230
  • [8] Database size and power to detect safety signals in pharmacovigilance
    Harnmond, Isaac W.
    Gibbs, Trevor G.
    Seifert, Harry A.
    Rich, Donna S.
    EXPERT OPINION ON DRUG SAFETY, 2007, 6 (06) : 713 - 721
  • [9] Potential safety signals for antibacterial agents from the Brazilian national pharmacovigilance database (Vigimed/VigiFlow)
    Barbosa, Luiza Hoehl Loureiro Alves
    Silva, Alice Ramos Oliveira
    Carvalho-Assef, Ana Paula D'Alincourt
    Lima, Elisangela Costa
    da Silva, Fabricio Alves Barbosa
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] The Cardiovascular Safety of Diabetes Drugs - Insights from the Rosiglitazone Experience
    Hiatt, William R.
    Kaul, Sanjay
    Smith, Robert J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14) : 1285 - 1287